



Biotech Daily

Thursday September 26, 2024

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: PARADIGM UP 14%; CURVEBEAM DOWN 6%**
- * **ONCOSIL: TRIPP-FFX, PANCOSIL TRIALS 'HALF-WAY'**
- * **TISSUE REPAIR TO LOSE ALL 3 INDEPENDENT DIRECTORS**
- * **INSIGNIA TAKES 10.2% OF IMMUTEP**
- * **BVF, MARK LAMPERT DILUTED TO 8.4% OF ACTINOGEN**
- * **THORNEY, TIGA 'BELOW 5% OF ENLITIC'**

MARKET REPORT

The Australian stock market was up 0.95 percent on Thursday September 26, 2024, with the ASX200 up 77.3 points to 8,203.7 points.

Twenty-four of the Biotech Daily Top 40 companies were up, 11 fell and five traded unchanged. All three Big Caps were up.

Yesterday's 1.5 cents or 7.9 percent worst, Paradigm, was the best, up 2.5 cents or 14.3 percent to 20 cents, with 4.6 million shares traded.

Actinogen and Dimerix were up more than eight percent; Nanosonics climbed six percent; Mesoblast improved 5.8 percent; Cynata was up 4.9 percent; Aroa, Avita, Cochlear, Impedimed, Neuren, Polynovo and Telix were up more than three percent; Imugene, Nova Eye, Prescient, Pro Medicus and Resonance rose more than two percent; 4D Medical, CSL, Immutep, Micro-X, Opthea and Percheron were up one percent or more; with Clarity, Proteomics and Resmed up by less than one percent.

Curvebeam led the falls, down one cent or 5.7 percent to 16.5 cents, with 289,729 shares traded.

Atomo and Medical Developments fell more than four percent; Emvision and Orthocell were down more than three percent; Medadvisor and Syntara shed more than two percent; Compumedics, Cyclopharm and Starpharma were down one percent or more; with Clinuvel down by 0.1 percent.

ONCOSIL MEDICAL

Oncosil says it has recruited 40 patients of 80 patients in its Tripp-FFX trial, and reached halfway in its Pancosil trial, with the tenth patient treated.

Last year, Oncosil said that it had enrolled the first of 80 patients in its 'Tripp-FFX', open-label, randomized trial of phosphorous-32 radiation with chemotherapy for pancreatic cancer (BD: May 3, 2023).

In April, the company said the Tripp-FFX study would assess the safety and efficacy of its device when given with Folfirinox (folinic acid, fluorouracil, irinotecan and oxaliplatin) chemotherapy for pancreatic cancer (BD: Apr 12, 2024).

Today, Oncosil said it had randomized the fortieth Tripp-FFX patient at the Christie National Health Service (NHS) Foundation Trust, in collaboration with Manchester University NHS Foundation Trust.

Last year, the company said it had ethics approval for its investigator-led 'Pancosil' trial of percutaneously applied radiotherapy for pancreatic cancer (BD: Jun 5, 2023).

In June, Oncosil said the trial at the Amsterdam University Medical Centre would enrol up to 20 patients assessing the safety and feasibility of computed tomography-guided percutaneous therapy using its device in patients with non-progressive, locally-advanced pancreatic cancer (BD: Jun 11, 2024).

Oncosil chief executive officer Nigel Lange said the company was "thrilled to have reached these critical milestones in both the Tripp-FFX and Pancosil trials".

"The dedication of our clinical partners is pivotal as we move closer to completing recruitment and advancing towards final data readouts," Mr Lange said.

"Reaching 50 percent recruitment in both trials is a testament to the potential of [the Oncosil device]," Mr Lange said.

Oncosil was unchanged at 1.3 cents with 2.7 million shares traded.

TISSUE REPAIR

Tissue Repair says independent directors Jack Lowenstein, Bryan Gray and Dr Michael Silberberg will resign at the close of its annual general meeting on October 25, 2024.

In August, the Federal Takeovers Panel said that it had received an application from Tissue Repair relating to a potential board spill request and concerning an alleged undisclosed association between requisitioning shareholders (BD: Aug 30, 2024).

Last week, Takeovers Panel chief executive Allan Bulman said the Panel "declined to conduct proceedings on an application dated August 28, from Tissue Repair in relation to its affairs, after accepting an undertaking from shareholders Spark Capital Pty Ltd and [executive director Tony] Charara" not to spill the board (BD: Sep 23, 2024).

The Takeovers Panel said it refused a review of its decision to decline proceedings against executive director Mr Charara and associated investors (BD: Sep 25, 2024).

The company said it received the notices following a proposal from Mr Charara that Tissue Repair delist from the ASX, which was not supported by the independent directors. Tissue Repair said that the independent directors were "not aware of any disagreement with Mr Charara other than their opposition to the delisting proposal he put forward in June 2024, and [were] pleased with Mr Charara's public confirmation that the company [would] remain within ASX's disclosure regime and governance principles".

The company said that a "key component in any company's best interests is that its board and chief executive officer trust each other".

"The three independent directors now intend to resign as at the close of the company's AGM on Friday October 25, 2024," Tissue Repair said.

Tissue Repair fell one cent or 2.7 percent to 36 cents.

IMMUTEP

The Melbourne-based Insignia Financial Ltd says it has increased its shareholding in Immutep from 127,728,455 shares (8.97%) to 147,623,939 shares (10.16%).

Insignia said it bought and sold shares with Onepath Funds, Anatares Capital, MLC Investments and the IOOF (Independent Order of Odd Fellows) between June 12 and September 20, 2024, with the single largest purchase on September 20 of 4,553,526 shares for \$1,548,710 or 34.0 cents a share.

Immutep was up half a cent or 1.5 percent to 34.5 cents with 3.8 million shares traded.

ACTINOGEN MEDICAL

San Francisco's BVF Partners says its 247,334,680 share-holding in Actinogen has been diluted from 9.79 percent to 8.40 percent.

Earlier this month, Actinogen said it hoped to raise \$11.1 million at 3.0 cents a share, in a \$8.1 million placement and a \$3.0 million entitlement offer (BD: Sep 18, 2024).

Actinogen was up 0.2 cents or 8.7 percent to 2.5 cents with 26.3 million shares traded.

ENLITIC

Melbourne's Thorney, Thorney Investment Group Australia (TIGA) and related parties say they have ceased their substantial shareholding in Enlitic.

Thorney and TIGA said that between August 13 and September 24, 2024 they sold 1,456,696 shares for \$96,082 or an average of 6.6 cents a share.

In their previous filing, last year, Thorney and Tiga said they held 6,235,250 shares or 7.23 percent (BD: Jan 21, 2024).

Biotech Daily understands that following the previous filing Thorney and Tiga held 5,671,930 Enlitic shares.

According to its most recent filing, Enlitic had 78,716,502 Chess depository instruments (CDIs) and 7,558,404 US shares on issue and Biotech Daily calculates that Thorney and Tiga retain 4,215,234 shares or 4.89 percent of the company.

Enlitic was unchanged at six cents.